Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 9, 2014, Pages 1735-1743

  Kanoun, Salim ^a   Rossi, Cédric ^b   Berriolo Riedinger, Alina ^a   Dygai Cochet, Inna ^a   Cochet, Alexandre ^a   Humbert, Olivier ^a   Toubeau, Michel ^a   Ferrant, Emmanuelle ^b   Brunotte, François ^a   Casasnovas, René Olivier ^b,c  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b HÔPITAL DU BOCAGE   (France)

^c UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

Hodgkin lymphoma; Interim PET; Metabolic tumour volume; SUVmax

Indexed keywords

BLEOMYCIN; FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HODGKIN DISEASE; HUMAN; LIVER CELL CARCINOMA; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR VOLUME; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; STATISTICAL MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR BURDEN; YOUNG ADULT;

EID: 84906044293     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2783-x     Document Type: Article

References (40)

1. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998;339:1506-14.
2. Specht L, Nordentoft AM, Cold S, Clausen NT, Nissen NI. Tumor burden as the most important prognostic factor in early stage Hodgkin's disease. Relations to other prognostic factors and implications for choice of treatment. Cancer. 1988;61:1719-27. (Pubitemid 18091802)
3. Willett CG, Linggood RM, Leong JC, Miketic LM, Stracher MA, Skates SJ, et al. Stage IA to IIB mediastinal Hodgkin's disease: three-dimensional volumetric assessment of response to treatment. J Clin Oncol. 1988;6:819-24.
4. Gobbi PG, Ghirardelli ML, Solcia M, Di Giulio G, Merli F, Tavecchia L, et al. Image-aided estimate of tumor burden in Hodgkin's disease: evidence of its primary prognostic importance. J Clin Oncol. 2001;19:1388-94. (Pubitemid 32202545)
5. Gobbi PG, Broglia C, Di Giulio G, Mantelli M, Anselmo P, Merli F, et al. The clinical value of tumor burden at diagnosis in Hodgkin lymphoma. Cancer. 2004;101:1824-34. (Pubitemid 39314746)
6. Eichenauer DA, Engert A, Dreyling M; ESMO Guidelines Working Group. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22 Suppl 6:vi55-58.
7. Moog F, Bangerter M, Diederichs CG, Guhlmann A, Merkle E, Frickhofen N, et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology. 1998;206:475-81. (Pubitemid 28112964)
8. Zhang H, Wroblewski K, Liao S, Kampalath R, Penney BC, Zhang Y, et al. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer. Acad Radiol. 2013;20:32-40.
9. Hyun SH, Choi JY, Kim K, Kim J, Shim YM, Um S-W, et al. Volume-based parameters of 18F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection. Ann Surg. 2013;257:364-70.
10. Shum W-Y, Ding H-J, Liang J-A, Yen K-Y, Chen S-W, Kao C-H. Use of pretreatment metabolic tumor volumes on PET-CT to predict the survival of patients with squamous cell carcinoma of esophagus treated by curative surgery. Anticancer Res. 2012;32:4163-8.
11. Park GC, Kim JS, Roh J-L, Choi S-H, Nam SY, Kim SY. Prognostic value of metabolic tumor volume measured by 18F-FDG PET/CT in advanced-stage squamous cell carcinoma of the larynx and hypopharynx. Ann Oncol. 2013;24:208-14.
12. Song MK, Chung JS, Shin HJ, Lee SM, Lee SE, Lee HS, et al. Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Ann Hematol. 2012;91:697-703.
13. Song MK, Chung JS, Shin HJ, Moon JH, Lee JO, Lee HS, et al. Prognostic value of metabolic tumor volume on PET/CT in primary gastrointestinal diffuse large B cell lymphoma. Cancer Sci. 2012;103:477-82.
14. Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica. 2006;91:475-81.
15. Hutchings M, Barrington SF. PET/CT for therapy response assessment in lymphoma. J Nucl Med. 2009;50 Suppl 1:21S-30S.
16. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107:52-9. (Pubitemid 43053523)
17. Zinzani PL, Tani M, Fanti S, Alinari L, Musuraca G, Marchi E, et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol. 2006;17:1296-300. (Pubitemid 44288221)
18. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25:3746-52. (Pubitemid 47372616)
19. Kumar R, Maillard I, Schuster SJ, Alavi A. Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas. Radiol Clin North Am. 2004;42:1083-100. (Pubitemid 39361461)
20. Connors JM. Positron emission tomography in the management of Hodgkin lymphoma. Hematol Am Soc Hematol Educ Program. 2011;2011:317-22.
21. Rossi C, Kanoun S, Berriolo-Riedinger A, Dygai-Cochet I, Humbert O, Legouge C, et al. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients. J Nucl Med. 2014;55:569-73.
22. Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H, et al. WHO classification of tumours, vol. 2. Lyon: International Agency for Research on Cancer; 2008.
23. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-86. (Pubitemid 350002966)
24. Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181-200.
25. Meignan M, Sasanelli M, Casasnovas RO, Luminari S, Fioroni F, Coriani C, et al. Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. Eur J Nucl Med Mol Imaging. 2014. doi:10.1007/s00259-014-2705-y.
26. Lin C, Itti E, Haioun C, Petegnief Y, Luciani A, Dupuis J, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med. 2007;48:1626-32. (Pubitemid 47572710)
27. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32-5.
28. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960;20:36-46.
29. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-74. (Pubitemid 8054849)
30. Gobbi PG, Bassi E, Bergonzi M, Merli F, Coriani C, Iannitto E, et al. Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy. Hematol Oncol. 2012;30:194-9
31. Gobbi PG, Valentino F, Bassi E, Coriani C, Merli F, Bonfante V, et al. Chemoresistance as a function of the pretherapy tumor burden and the chemotherapy regimen administered: differences observed with two current chemotherapy regimens for advanced Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2011;11:396-402.
32. Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol. 2011;29:1844-54.
33. El-Galaly TC, d'Amore F, Mylam KJ, de Nully Brown P, Bøgsted M, Bukh A, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol. 2012;30:4508-14.
34. Song MK, Chung JS, Lee JJ, Jeong SY, Lee SM, Hong JS, et al. Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma. Cancer Sci. 2013;104:1656-61
35. Tseng D, Rachakonda LP, Su Z, Advani R, Horning S, Hoppe RT, et al. Interim-treatment quantitative PET parameters predict progression and death among patients with Hodgkin's disease. Radiat Oncol. 2012;7:5.
36. Lee P, Weerasuriya DK, Lavori PW, Quon A, Hara W, Maxim PG, et al. Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys. 2007;69:328-33. (Pubitemid 47380105)
37. Ciernik IF, Dizendorf E, Baumert BG, Reiner B, Burger C, Davis JB, et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys. 2003;57:853-63. (Pubitemid 37194314)
38. Nestle U, Kremp S, Schaefer-Schuler A, Sebastian-Welsch C, Hellwig D, Rübe C, et al. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-small cell lung cancer. J Nucl Med. 2005;46:1342-8. (Pubitemid 43733485)
39. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics. 1999;19:61-77.
40. Hatt M, Boussion N, Cheze-Le Rest C, Visvikis D, Pradier O. Metabolically active volumes automatic delineation methodologies in PET imaging: review and perspectives. Cancer Radiother. 2012;16:70-81.